ATR and melanoma: A trial with 58 patients, including 34 melanoma patients, investigated the use of AZD6738, an oral inhibitor of the serine/threonine protein kinase ATR (Ataxia Telangiectasia and Rad3 Related) to treat refractory advanced solid tumors in combination with weekly paclitaxel.